Literature DB >> 11126083

Prevalence of human papilloma virus genital infections in sexually transmitted diseases clinic attendees in Ibadan.

A O Okesola1, O I Fawole.   

Abstract

All patients, who presented at the Sexually Transmitted Disease clinic of the University College Hospital, Ibadan, between the period of August 1996 and January 1998 were included in this study. They were examined for genital infections in order to determine the prevalence rate of Human papilloma virus genital infection (genital warts) among them. Out of the 1,373 patients seen in the clinic during the period, 861 (62.71%) had STD while the remaining 512 (37.29%) had other conditions. Out of these 861 cases, 69 (8.01%) had HPV genital infection, while the remaining 792 (91.9%) had other STDS. Of these 69 cases of genital warts, 35 (50.7%) were males while 34 (49.3%) were females. Their ages ranged between 17 and 74 years, with the peak incidence in the 20-29 years age group. 32 (46.4%) had concurrent genital infections with non-gonococcal urethritis and cervicitis 9(13%) constituting the most common type. The highest incidence (36.2%) of this condition was found among petty traders while the lowest was found among the business executives and applicants. In 67 (97%) of these patients, the nature of sexual intercourse was vaginal, while in 1 (1.5%) it was oral and another 1 (1.5%) both vaginal and oral. 26 (37.7%) of the patients had just one sexual partner, while 7 (8.1%) had 2 or more. Only 2 (2.9%) admitted to have had any sexual contact with commercial sex workers. The sites of warts in males include the shaft of the penis, the glans penis, perineum and intrameatum. In females, warts were found in the vulva, vagina, cervix, perineum and perianal regions. 42 (60.9%) of these patients were placed on 20% podophyllin on tincture of benzoin, 17 (24.6%) on cryotherapy and 1 (1.5%) on both. They all did well on the different treatment regimens except for 1 (1.5%) that had to change from podophyllin to cryotherapy when there was no reduction in size. 11 (15.9%) were however lost to follow up.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126083

Source DB:  PubMed          Journal:  West Afr J Med        ISSN: 0189-160X


  6 in total

1.  Male circumcision is associated with a lower prevalence of human papillomavirus-associated penile lesions among Kenyan men.

Authors:  Danielle M Backes; Maaike C G Bleeker; Chris J L M Meijer; Michael G Hudgens; Kawango Agot; Robert C Bailey; J O Ndinya-Achola; Juma Hayombe; Cornelis J A Hogewoning; Stephen Moses; Peter J F Snijders; Jennifer S Smith
Journal:  Int J Cancer       Date:  2011-08-02       Impact factor: 7.396

2.  Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa.

Authors:  Bertran Auvert; Joelle Sobngwi-Tambekou; Ewalde Cutler; Marthi Nieuwoudt; Pascale Lissouba; Adrian Puren; Dirk Taljaard
Journal:  J Infect Dis       Date:  2009-01-01       Impact factor: 5.226

3.  Prevalence, incidence and risk factors for anogenital warts in Sub Saharan Africa: a systematic review and meta analysis.

Authors:  Cecily Banura; Florence M Mirembe; Jackson Orem; Anthony K Mbonye; Simon Kasasa; Edward K Mbidde
Journal:  Infect Agent Cancer       Date:  2013-07-10       Impact factor: 2.965

4.  Anogenital warts in Northern Nigeria: A ten-year Review.

Authors:  Saad Aliyu Ahmed; Mohammed Sani Shehu; Murtala Abubakar; Suleiman Eneyamire Dauda
Journal:  Niger Med J       Date:  2013-09

5.  Local risk factors in genital human papilloma virus infection in cervical smears.

Authors:  Ec Ojiyi; Ie Dike; C Okeudo; C Ejikem; Ac Nzewuihe; A Agbata
Journal:  Ann Med Health Sci Res       Date:  2013-10

6.  Reported oral and anal sex among adolescents and adults reporting heterosexual sex in sub-Saharan Africa: a systematic review.

Authors:  Imran O Morhason-Bello; Severin Kabakama; Kathy Baisley; Suzanna C Francis; Deborah Watson-Jones
Journal:  Reprod Health       Date:  2019-05-06       Impact factor: 3.223

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.